Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Warn PA, Felton TW, Perfect JR, Harrison TS, Hope WW.

Antimicrob Agents Chemother. 2013 Jun;57(6):2793-800. doi: 10.1128/AAC.00216-13. Epub 2013 Apr 9.

2.

Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.

Nguyen MH, Najvar LK, Yu CY, Graybill JR.

Antimicrob Agents Chemother. 1997 May;41(5):1120-3.

3.

Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Sorrell TC, Patterson TF.

Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.

4.

Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.

O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely MN, Harrison TS, Perfect JR, Hope WW.

J Infect Dis. 2013 Jul 15;208(2):351-61. doi: 10.1093/infdis/jit164. Epub 2013 Apr 18.

5.

Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.

Pfaller M, Zhang J, Messer S, Tumberland M, Mbidde E, Jessup C, Ghannoum M.

Diagn Microbiol Infect Dis. 1998 Nov;32(3):191-9.

PMID:
9884835
6.

Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.

Larsen RA, Bauer M, Thomas AM, Sanchez A, Citron D, Rathbun M, Harrison TS.

Antimicrob Agents Chemother. 2005 Aug;49(8):3297-301.

7.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
8.

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.

Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MA, Haubrich RH, Richie JA, Edwards JE Jr, Ghannoum MA.

Clin Infect Dis. 1996 Feb;22(2):322-8.

9.

Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.

Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.

J Med Assoc Thai. 2006 Jun;89(6):795-802.

PMID:
16850679
10.

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Perfect JR, Cox GM, Dodge RK, Schell WA.

Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3.

11.

Comparison of D0870 and fluconazole in the treatment of murine cryptococcal meningitis.

Correa AL, Velez G, Albert M, Luther M, Rinaldi MG, Graybill JR.

J Med Vet Mycol. 1995 Nov-Dec;33(6):367-74.

PMID:
8683404
13.
14.

Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.

Larsen RA, Bauer M, Thomas AM, Graybill JR.

Antimicrob Agents Chemother. 2004 Mar;48(3):985-91.

15.

Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.

Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, Ding JC, Rinaldi MG, Graybill JR.

Antimicrob Agents Chemother. 1996 Sep;40(9):2178-82.

16.

Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.

Lee CH, Chang TY, Liu JW, Chen FJ, Chien CC, Tang YF, Lu CH.

BMC Infect Dis. 2012 Dec 20;12:361. doi: 10.1186/1471-2334-12-361.

17.

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK Jr, Bartroli J, Perfect JR.

Antimicrob Agents Chemother. 2004 Feb;48(2):384-7.

18.

Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746.

Restrepo MI, Najvar LK, Barchiesi F, Luther MF, Graybill JR.

Med Mycol. 2000 Jun;38(3):221-4.

PMID:
10892990
19.

Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.

Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y.

J Antimicrob Chemother. 2004 Aug;54(2):563-5. Epub 2004 Jul 14.

20.

The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.

Wang H, Xu K, Liu L, Tan JP, Chen Y, Li Y, Fan W, Wei Z, Sheng J, Yang YY, Li L.

Biomaterials. 2010 Apr;31(10):2874-81. doi: 10.1016/j.biomaterials.2009.12.042. Epub 2009 Dec 31.

PMID:
20044131
Items per page

Supplemental Content

Write to the Help Desk